Centessa Pharmaceuticals 주식 가격. 0ACX - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

매수가

0.00

매도가

0.00

거래량

8,096

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

market_cap

전일 종가

0.00

개장가

최근 거래 시간

15.6443

(O)

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

발행 주식

0.00

배당수익률

주가수익률

0.00

주당순이익(EPS)

매출

6.85M

순이익

-151.09M

섹터

Coml Physical, Biologcl Resh

산업

Coml Physical, Biologcl Resh

웹사이트

www.centessa.com

본부

Cheshire, Gbr

설립됨

Centessa Pharmaceuticals Plc is listed in the Coml Physical, Biologcl Resh sector of the 런던증권거래소 with ticker 0ACX. The last closing price for Centessa Pharmaceuticals was US$0. Over the last year, Centessa Pharmaceuticals shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Centessa Pharmaceuticals currently has 0 shares in issue.

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update Announced additional interim data...

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 12...

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 11, 2024 (GLOBE...

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived...

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 Company advancing pipeline of potential...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0ACX - Frequently Asked Questions (FAQ)

What is the current Centessa Pharmaceuticals share price?

The current share price of Centessa Pharmaceuticals is US$ 0.00

What is the 1 year trading range for Centessa Pharmaceuticals share price?

Centessa Pharmaceuticals has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the reporting currency for Centessa Pharmaceuticals?

Centessa Pharmaceuticals reports financial results in USD

What is the latest annual turnover for Centessa Pharmaceuticals?

The latest annual turnover of Centessa Pharmaceuticals is USD 6.85M

What is the latest annual profit for Centessa Pharmaceuticals?

The latest annual profit of Centessa Pharmaceuticals is USD -151.09M

What is the registered address of Centessa Pharmaceuticals?

The registered address for Centessa Pharmaceuticals is 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE, WA14 2DT

What is the Centessa Pharmaceuticals website address?

The website address for Centessa Pharmaceuticals is www.centessa.com

Which industry sector does Centessa Pharmaceuticals operate in?

Centessa Pharmaceuticals operates in the COML PHYSICAL, BIOLOGCL RESH sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ADMEAdm Energy Plc	0.35p (59.09%)	9.76M
WSGWestminster Group Plc	1.40p (27.27%)	3.23M
EUAEurasia Mining Plc	6.20p (22.77%)	33.44M
WHRWarehouse Reit Plc	98.90p (16.63%)	13.38M
MET1Metals One Plc	0.575p (15.00%)	3.65M
BUCBuilt Cybernetics Plc	1.60p (-81.18%)	520k
SAVESavannah Energy Plc	9.65p (-63.24%)	238.56M
TIGTeam Internet Group Plc	54.30p (-44.93%)	5.38M
VELAVela Technologies Plc	0.0029p (-42.00%)	1.51B
ALBAAlba Mineral Resources	0.0135p (-27.03%)	152.03M
VELAVela Technologies Plc	0.0029p (-42.00%)	1.51B
TRPTower Resources Plc	0.023p (-2.13%)	336.13M
CORCorpus Resources Plc	0.0145p (3.57%)	267.93M
SAVESavannah Energy Plc	9.65p (-63.24%)	238.56M
GWMOGreat Western Mining Corporation Plc	0.01p (11.11%)	234.69M

Jaguarjacket 5 분 전

ADIAs Florida clinic has exceeded financial expectations in its first month of operation!

ADIA

LTListener 5 분 전

Assumption is they are not paying for a transfer agent.. again another sign they may not head back directly to the OTC.

“We intend to raise sufficient capital to become current and stay current “

“We intend to enter into at least one strategic transaction”

RSPI

GolfnutBoston 7 분 전

I'm not going to rant about anything lol.
I don't care about any of this. I would like my money back but that probably won't happen.

AFFU

arizona1 7 분 전

She must have paid in Rubles!

cojoboy 8 분 전

Ya know I happen to sell at the high or buy at th low maybe 5% of the time..but they still give chit

RDAR

arizona1 9 분 전

https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:o6tn5qlfgilxlhihzsedlnuj/bafkreibqyjns6kzmapsglpxtazs2nrmygnfdksihcpnyyiptq67ryxnqaa@jpeg

Zorax 11 분 전

I'm hoping some dems found spines and didn't show up in notable numbers.

looking 4 a win 11 분 전

I'm screwed! Market will never drop again after that speech.

UVIX

NeutrinoKid 11 분 전

However the market cap on the otcmarket site was updated yesterday, to 1,898,927$. Divided by the OS from November one gets exactly the current SP, 0.002$.

https://www.otcmarkets.com/stock/RSPI/security

RSPI

janice shell 11 분 전

President Donald Trump will “probably” announce tariff compromise deals with Canada and Mexico soon, Commerce Secretary Howard Lutnick said Tuesday.
The potential agreements would likely involve scaling back at least part of Trump’s brand new 25% tariffs on imports from Mexico and Canada, he

Sell4Profit 12 분 전

ARBB up 113 percent ah on 45m contract.
$1.06
Wishing I hadn't sold.

ARB IOT GROUP LIMITED SECURES ORDER WORTH APPROXIMATELY US$45 MILLION FOR AI DATA CENTRE SERVER SOLUTION

ARBB

kym1216 12 분 전

Okay so you're broke lmao

HWNI

TJG 13 분 전

He is not in charge Rohan was the interim CEO but he turned the running of OneMind over to Thierry just after Balkin took over This is Thierry official position now. OneMind as a subsidiary of Affluence no longer has a CEO. This info has been posted on LinkedIn for a while. And they are not obligate

AFFU

rooster 14 분 전

Not really I should have put my lol after it

WinstonCup 14 분 전

Yeah, he won't get any respect right now.

CFSU

StockItOut 15 분 전

You don't even know what it says. Chump keeps making claims with no substance o show.

XERI

arizona1 16 분 전

hehehe I guess I touched a nerve.

Zorax 16 분 전

Every single person in that article has a special massive interest in bitcoin/cryptocurrency because they are all heavily invested in a scam entity. Every one.
And each of them want to enrich themselves first directly.

Nothing about cryptocurrency has any value to the average

ergo sum 17 분 전

Used to be a solid democratic place. Ironically there are lots of windmills there.

Truenorth2016 17 분 전

Look what Stock Titan Says about GCAN Merger with SYTA....This news critic says there is no negatives even though some one this board will find some....LOL....The Article confims GCAN CEO is bringing $80 Million Dollars in Revenues to the merger......But yet people on this boards is saying GCAN CEO

GCAN SYTA

kBletsgo30 18 분 전

What kind of props could we be looking at if it is a buyout?

RSPI

ergo sum 18 분 전

Nobody’s ever seen anything like it…..

arizona1 18 분 전

It's a close call, Peg!

Ethical Concerns Surround Sen. Joni Ernst’s Relationships With Top Military Officials Who Lobbied Her Committee

Ernst, an Iowa Republican, is one of the most influential voices in Congress on military topics. Ethics and military experts say her

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Centessa Pharmaceuticals Plc (0ACX)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Centessa Pharmaceuticals Plc 정보

0ACX 최신 뉴스

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Centessa Pharmaceuticals Plc (0ACX) 시세

Centessa Pharmaceuticals Plc (0ACX)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Centessa Pharmaceuticals Plc 정보

0ACX 최신 뉴스

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE